Gilead Sciences, Inc. (GILD)
NASDAQ: GILD · Real-Time Price · USD
107.37
+0.63 (0.59%)
At close: May 23, 2025, 4:00 PM
106.60
-0.77 (-0.72%)
After-hours: May 23, 2025, 7:46 PM EDT
Gilead Sciences Employees
Gilead Sciences had 17,600 employees as of December 31, 2024. The number of employees decreased by 400 or -2.22% compared to the previous year.
Employees
17,600
Change (1Y)
-400
Growth (1Y)
-2.22%
Revenue / Employee
$1,632,670
Profits / Employee
$338,920
Market Cap
133.56B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
GILD News
- 16 hours ago - ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors - Business Wire
- 2 days ago - Gilead Sciences, Inc. (GILD) RBC Capital Markets Global Healthcare Conference (Transcript) - Seeking Alpha
- 8 days ago - Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and EHA - Business Wire
- 10 days ago - Gilead Sciences, Inc. (GILD) BofA Securities Health Care Conference Transcript - Seeking Alpha
- 11 days ago - Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet - Seeking Alpha
- 16 days ago - Gilead announces $11 billion in new investments in US - Reuters
- 16 days ago - Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment - Business Wire
- 16 days ago - Gilead's Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025 - Business Wire